Valion Bio Announces Changes to Management and Board of Directors
(PR-inside.com) Current CFO, Lisa Wolf named President and COO, assuming expanded executive and operational leadership. Jared Malbin and Thomas Jensen appointed as directors. Lead Asset Positioned for Significant Markets: Entolimod targets the projected $7.8 billion Acute Radiation Syndrome ("ARS") market by 2032 and a…
Solo un extracto — este editor licencia su texto. Lea el comunicado completo en la fuente.
Plan Gratis · Plus 29 CA$ o Pro 99 CA$/mes


